Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 55% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
The mean of analysts' price targets for Immunovant (IMVT) points to a 47.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Share Offerings Prompt Huge Insider Buying in These 3 Biotechs
In the past week or so, secondary offerings from biotechs Immunovant Inc. (NASDAQ: IMVT), Kymera Therapeutics Inc.
Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement
Immunovant (IMVT) shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential best-in-class IgG reductions. I downgrade IMVT from "Strong Buy" to "Buy" due to competitive TED landscape and de-emphasis on batoclimab, despite robust upcoming catalysts. IMVT-1402 aims to address unmet needs in relapsed or uncontrolled GD patients, with pivotal data readouts expected in 2027 for additional indications like Myasthenia Gravis and difficult-to-treat rheumatoid arthritis.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Immunovant, Inc. (IMVT) Q2 2026 Earnings Call Transcript
Immunovant, Inc. ( IMVT ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Conference Call Participants Stephanie Lee Griffin - Roivant Sciences Ltd. Matthew Gline - Roivant Sciences Ltd.
Immunovant (IMVT) Up 7.8% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results
Immunovant stock jumps 11% after new batoclimab study results showed durable thyroid hormone control in Graves' disease patients.
